Johnson & Johnson stock gains as guidance points to 2026 revenue above USD 100 billion

{
  "signal_id": "48ee6c18-d5d0-f950-1f00-abf868fcf021",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-09-15T12:28:36+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/johnson-and-johnson-stock-gains-as-guidance-points-to-2026-revenue-above/70105356",
    "title": "Johnson & Johnson stock gains as guidance points to 2026 revenue above USD 100 billion - ad-hoc-news.de",
    "excerpt": "Johnson & Johnson stock (ISIN US4781601046) is trading close to its 52-week high as of September 15, 2026, while management is guiding for adjusted operational sales growth of 6.5% and adjusted EPS growth of 7.3% for 2026, with annual revenue expected to exceed USD 100 billion for the first time. Investing.com reports that this long-range growth case was outlined at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. According to Investing.com on September 14, 2026, Johnson & Johnson used the Morgan Stanley 24th Annual Global Healthcare Conference to outline guidance for 2026 adjusted operational sales growth of 6.5% and adjusted EPS growth of 7.3%, signaling mid-single-digit to high-single-digit expansion in its core metrics. In the same conference appearance, executives indicated that total revenue in 2026 is projected to surpass USD 100 billion for the first time in the company’s history, framing 2027 as even stronger than 2026 and targeting double-digit growth by the end of the decade. Investing.com notes that this path relies on new drug launches and a focused portfolio rather than major mergers and acquisitions. Johnson & Johnson’s latest reported quarter also supports the optimism embedded in its guidance. As MarketBeat highlights on September 15, 2026, the company delivered adjusted EPS of USD 2.90 and revenue of USD 25.31 billion in its...",
    "summary": "Johnson & Johnson reported adjusted EPS of USD 2.90 on revenue of USD 25.31 billion in its most recent quarter.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2671657_1920_1080.webp",
    "confidence": 0.9,
    "published_at": "2026-09-15T12:28:36Z",
    "article_sentence": "As MarketBeat highlights on September 15, 2026, the company delivered adjusted EPS of USD 2.90 and revenue of USD 25.31 billion in its most recent quarter, topping consensus estimates of USD 2.84 per share and USD 25.06 billion in revenue."
  }
}

curl https://signals.autobound.ai/v1/signals/48ee6c18-d5d0-f950-1f00-abf868fcf021 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'